Aflibercept biosimilar SB15 improved retinal anatomy while preserving vision in both treatment-naïve and switching patients with nAMD, RVO, and DME. Aflibercept 2 mg biosimilar SB15 (Afilivu; Samsung ...
Real-world natalizumab biosimilar switching preserved relapsing-remitting MS outcomes but lowered treatment satisfaction, ...
Real-world data shows rituximab biosimilars for membranous nephropathy match remission rates, cut costs, and expand treatment options. A lower-cost biosimilar of rituximab produced remission rates on ...
Early use of ustekinumab biosimilars in Spain shows cost-effective Crohn disease care, boosting QALYs and cutting NHS spend—insights for Europe. Patients with moderate to severe Crohn disease in Spain ...
Biosimilar anti-VEGF agents matched the reference ranibizumab in vision outcomes and safety across retinal diseases in India, at a lower cost. More than half of India's health care spending is paid ...
Phase 3 data show denosumab biosimilar KN012 matches Prolia for BMD gains and safety, potentially expanding affordable osteoporosis care. For postmenopausal women managing osteoporosis, the high cost ...
Trial data show switching between ABP 654 and reference ustekinumab maintains similar psoriasis control, safety, and immunogenicity, supporting FDA interchangeability confidence. Patients with ...
FDA expands Tofidence uses, Teva launches Eylea biosimilar in Europe, and Alvotech’s Entyvio rival enters FDA review—boosting access. Biosimilar developers across the globe advanced their pipelines ...
Regeneron appeals legal decision after judge refuses to block an aflibercept biosimilar; Prime Therapeutics, a pharmacy benefit manager (PBM), becomes the latest to offer biosimilars referencing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results